Prognostic and Predictive Potential of CCL5 Expression in Muscle-Invasive Bladder Cancer Patients.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
07 Jun 2024
Historique:
received: 10 04 2024
revised: 31 05 2024
accepted: 04 06 2024
medline: 27 6 2024
pubmed: 27 6 2024
entrez: 27 6 2024
Statut: epublish

Résumé

Bladder cancer (BC) is the 12th most commonly diagnosed cancer worldwide. Although there are several well-established molecular and immunological classifications, prognostic and predictive markers for tumor cells and immune cells are still needed. Using a tissue microarray, we analyzed the expression of the chemokine CC motif ligand 5 (CCL5) by immunohistochemistry (IHC) in 175 muscle-invasive BC samples. The application of a single cutoff for the staining status of tumor cells (TCs; positive vs. negative) and immune cells (ICs; positive vs. negative) revealed 75 patients (42.9%) and 123 patients (70.3%) with CCL5-positive TCs or ICs, respectively. IHC results were associated with prognostic and predictive data. Multivariate Cox regression analysis revealed that positive CCL5 staining in TCs was associated with significantly shorter disease-specific survival (DSS; RR = 1.51;

Identifiants

pubmed: 38928033
pii: ijms25126325
doi: 10.3390/ijms25126325
pii:
doi:

Substances chimiques

Chemokine CCL5 0
Biomarkers, Tumor 0
CCL5 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Rudolf und Irmgard Kleinknecht-Stiftung
ID : none
Organisme : Johannes und Frieda Marohn-Stiftung
ID : none
Organisme : Wilhelm Sander-Stiftung
ID : none
Organisme : Deutsche Forschungsgemeinschaft
ID : TA 145/17-1

Auteurs

Cedric Smolka (C)

Institute of Pathology, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.
Department of Urology and Pediatric Urology, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.

Markus Eckstein (M)

Institute of Pathology, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.
Comprehensive Cancer Center EMN, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.
Bridge Consortium, 68135 Mannheim, Germany.

Rudolf Jung (R)

Institute of Pathology, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.

Verena Lieb (V)

Department of Urology and Pediatric Urology, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.
Comprehensive Cancer Center EMN, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.

Danijel Sikic (D)

Department of Urology and Pediatric Urology, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.
Comprehensive Cancer Center EMN, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.
Bridge Consortium, 68135 Mannheim, Germany.

Robert Stöhr (R)

Institute of Pathology, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.
Comprehensive Cancer Center EMN, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.
Bridge Consortium, 68135 Mannheim, Germany.

Veronika Bahlinger (V)

Institute of Pathology, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.

Simone Bertz (S)

Institute of Pathology, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.
Comprehensive Cancer Center EMN, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.

Astrid Kehlen (A)

Molecular Diagnostic Section Unit III, Department of Laboratory Medicine, Halle University Hospital, 06097 Halle (Saale), Germany.

Arndt Hartmann (A)

Institute of Pathology, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.
Comprehensive Cancer Center EMN, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.
Bridge Consortium, 68135 Mannheim, Germany.

Bernd Wullich (B)

Department of Urology and Pediatric Urology, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.
Comprehensive Cancer Center EMN, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.
Bridge Consortium, 68135 Mannheim, Germany.

Helge Taubert (H)

Department of Urology and Pediatric Urology, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.
Comprehensive Cancer Center EMN, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.
Bridge Consortium, 68135 Mannheim, Germany.

Sven Wach (S)

Department of Urology and Pediatric Urology, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.
Comprehensive Cancer Center EMN, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.
Bridge Consortium, 68135 Mannheim, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH